Pharmacy, PBMs & Pricing
Expert articles and analysis related to pharmacy, pbms & pricing.
AI Summary — Last 24 Hours
Synthesis:
In the past 24 hours, pressure on pharmacy benefit management and drug pricing intensified as employers increasingly consider switching pharmacy vendors due to surging healthcare costs, raising stakes for payers and value-based care (VBC) partnerships striving to control total cost of care [Healthcare Dive: employers switching vendors]. Simultaneously, expanding access to GLP-1 therapies via digital platforms such as Walmart’s Better Care Services introduces immediate downstream impacts on population health management, medication adherence, and VBC performance measures—amplifying the urgency for ACOs, Medicare Advantage, and Medicaid plans to rapidly adapt formularies, risk stratification, and patient engagement models to keep pace with evolving market dynamics [MobiHealthNews: Walmart expands Better Care Services].
Related Articles
Rising Drug Prices Mean Consumers Bear the Cost
Rising Drug Prices Mean Consumers Bear the Cost  AHIP
Today’s Hearing: Drugmakers Want a Blank Check to Keep Overcharging Americans
Today’s Hearing: Drugmakers Want a Blank Check to Keep Overcharging Americans  AHIP
AHIP Statement for the Record | 4.16.26 HELP: "Making Medicines More…
AHIP Statement for the Record | 4.16.26 HELP: "Making Medicines More…  AHIP
STAT+: Researchers behind GLP-1 obesity drugs advance new approach: Drop GLP-1 as a target
Scientists are raising a provocative hypothesis about GLP-1 drugs for obesity: Perhaps targeting the GLP-1 hormone isn't actually necessary to achieve effective weight loss.
FDA moves toward easing restrictions on certain peptides
The agency’s decision to hold an advisory committee meeting on the topic comes after HHS Secretary Robert F. Kennedy Jr. told podcaster Joe Rogan he’s a “big fan” of peptides.
340B in 2026: Access in an Uncertain Policy Environment
340B in 2026: Access in an Uncertain Policy Environment  Health Leaders Media
DiMe leads effort to create standards for cash-pay drug models
DiMe leads effort to create standards for cash-pay drug models  Fierce Healthcare
STAT+: Travere’s drug for a kidney disease doesn’t improve kidney function. The FDA approved it anyway
How a rare disease drugmaker won FDA approval after a clinical trial disappointed.
Smarter Oncology Management Needed as Costs Continue to Climb
Smarter Oncology Management Needed as Costs Continue to Climb  AJMC
Walmart expands digital health platform’s weight loss offerings, including GLP-1 prescribing
Customers can now connect to third-party providers for weight management services through Walmart’s digital health platform, then turn around and fill GLP-1 prescriptions at its retail pharmacy.